These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 2943338

  • 1. Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen.
    Harris AL, Dowsett M, Cantwell BM, Sainsbury JR, Needham G, Farndon J, Wilson R.
    Breast Cancer Res Treat; 1986; 7 Suppl():S69-72. PubMed ID: 2943338
    [Abstract] [Full Text] [Related]

  • 2. Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer.
    Harris AL, Dowsett M, Smith IE, Jeffcoate S.
    Eur J Cancer Clin Oncol; 1984 Apr; 20(4):463-9. PubMed ID: 6233150
    [Abstract] [Full Text] [Related]

  • 3. A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
    Dowsett M, Harris AL, Stuart-Harris R, Hill M, Cantwell BM, Smith IE, Jeffcoate SL.
    Br J Cancer; 1985 Oct; 52(4):525-9. PubMed ID: 2933050
    [Abstract] [Full Text] [Related]

  • 4. Low dose aminoglutethimide (125 mg twice daily) with hydrocortisone for the treatment of advanced postmenopausal breast cancer.
    Harris AL, Cantwell BM, Sainsbury JR, Needham G, Evans RG, Dawes PJ, Wilson R, Farndon J.
    Breast Cancer Res Treat; 1986 Oct; 7 Suppl():S41-4. PubMed ID: 3742063
    [Abstract] [Full Text] [Related]

  • 5. Endocrine effects of aminoglutethimide plus hydrocortisone versus effects of high dose of hydrocortisone alone in postmenopausal metastatic breast cancer.
    Alexieva-Figusch J, de Jong FH, Lamberts WJ, van Gilse HA, Klign JG.
    Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1349-56. PubMed ID: 2960533
    [Abstract] [Full Text] [Related]

  • 6. Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.
    Harris AL, Dowsett M, Smith IE, Jeffcoate SL.
    Br J Cancer; 1983 May; 47(5):621-7. PubMed ID: 6221746
    [Abstract] [Full Text] [Related]

  • 7. Aminoglutethimide dose and hormone suppression in advanced breast cancer.
    Harris AL, Dowsett M, Jeffcoate SL, Smith IE.
    Eur J Cancer Clin Oncol; 1983 Apr; 19(4):493-8. PubMed ID: 6222901
    [Abstract] [Full Text] [Related]

  • 8. Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer.
    Stuart-Harris R, Dowsett M, D'Souza A, Donaldson A, Harris AL, Jeffcoate SL, Smith IE.
    Clin Endocrinol (Oxf); 1985 Feb; 22(2):219-26. PubMed ID: 2985301
    [Abstract] [Full Text] [Related]

  • 9. Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer.
    Harris AL, Dowsett M, Jeffcoate SL, McKinna JA, Morgan M, Smith IE.
    J Clin Endocrinol Metab; 1982 Oct; 55(4):718-22. PubMed ID: 6213633
    [Abstract] [Full Text] [Related]

  • 10. Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy.
    Dowsett M, Harris AL, Smith IE, Jeffcoate SL.
    J Clin Endocrinol Metab; 1984 Jan; 58(1):99-104. PubMed ID: 6227629
    [Abstract] [Full Text] [Related]

  • 11. Aminoglutethimide in the treatment of advanced breast cancer.
    Stuart-Harris RC, Smith IE.
    Cancer Treat Rev; 1984 Sep; 11(3):189-204. PubMed ID: 6241038
    [No Abstract] [Full Text] [Related]

  • 12. Aminoglutethimide as second line therapy in advanced breast cancer.
    Elomaa I, Blomqvist C, Rissanen P.
    Breast Cancer Res Treat; 1986 Sep; 7 Suppl():S51-4. PubMed ID: 3017481
    [Abstract] [Full Text] [Related]

  • 13. Steroid hormone profiles in women treated with aminoglutethimide for metastatic carcinoma of the breast.
    Samojlik E, Santen RJ, Kirschner MA, Ertel NH.
    Cancer Res; 1982 Aug; 42(8 Suppl):3349s-3352s. PubMed ID: 7083199
    [Abstract] [Full Text] [Related]

  • 14. Second line endocrine treatment of postmenopausal advanced breast cancer. Preliminary endocrine results of a 5-arm randomized phase II trial of medium vs low dose aminoglutethimide, with or without hydrocortisone vs hydrocortisone alone (EORTC 10861).
    Bruning PF, Bonfrèr JM, Wildiers J, Jassem J, Beex LV, Schornagel J, Nooijen WJ.
    J Steroid Biochem Mol Biol; 1990 Dec 20; 37(6):1013-9. PubMed ID: 2149501
    [Abstract] [Full Text] [Related]

  • 15. Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone.
    Rose C, Kamby C, Mouridsen HT, Bastholt L, Brincker H, Skovgaard-Poulsen H, Andersen AP, Loft H, Dombernowsky P, Andersen KW.
    Breast Cancer Res Treat; 1986 Dec 20; 7 Suppl():S45-50. PubMed ID: 3527306
    [Abstract] [Full Text] [Related]

  • 16. Low-dose aminoglutethimide in treatment of advanced breast cancer.
    Stuart-Harris R, Dowsett M, Bozek T, McKinna JA, Gazet JC, Jeffcoate SL, Kurkure A, Carr L, Smith IE.
    Lancet; 1984 Sep 15; 2(8403):604-7. PubMed ID: 6147642
    [Abstract] [Full Text] [Related]

  • 17. Low-dose aminoglutethimide in postmenopausal breast cancer: effects on adrenal and thyroid hormone secretion.
    Dowsett M, Mehta A, Cantwell BM, Harris AL.
    Eur J Cancer; 1991 Sep 15; 27(7):846-9. PubMed ID: 1657077
    [Abstract] [Full Text] [Related]

  • 18. Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer.
    Santen RJ, Samojlik E, Lipton A, Harvey H, Ruby EB, Wells SA, Kendall J.
    Cancer; 1977 Jun 15; 39(6 Suppl):2948-58. PubMed ID: 194681
    [Abstract] [Full Text] [Related]

  • 19. Adrenal suppression with aminoglutethimide. II. Differential effects of aminoglutethimide on plasma androstenedione and estrogen levels.
    Samojlik E, Santen RJ, Wells SA.
    J Clin Endocrinol Metab; 1977 Sep 15; 45(3):480-7. PubMed ID: 903399
    [No Abstract] [Full Text] [Related]

  • 20. Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.
    Samojlik E, Veldhuis JD, Wells SA, Santen RJ.
    J Clin Invest; 1980 Mar 15; 65(3):602-12. PubMed ID: 6986409
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.